Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab phase 3 study in adults with moderate to severe chronic plaque psoriasis
jRCT2080225270Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of bimekizumab in psoriasis (3 arms), sponsored by UCB. Primary endpoints: PASI90 response at week 16 and IGA response at week 16. Started Jul 2020; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on jRCT2080225270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225270.